Comparative Pharmacology
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MANGANESE SULFATE.
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MANGANESE SULFATE.
CUPRIC CHLORIDE vs MANGANESE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Copper is an essential trace element that serves as a cofactor for various enzymes, including cytochrome c oxidase (involved in mitochondrial respiration), superoxide dismutase (antioxidant defense), ceruloplasmin (iron metabolism), and lysyl oxidase (collagen cross-linking). It also participates in neurotransmitter synthesis and maintenance of vascular integrity.
Manganese sulfate is a source of manganese, a trace element that acts as a cofactor for various enzymes including arginase, pyruvate carboxylase, and superoxide dismutase. It is essential for normal bone formation, blood clotting, and nervous system function.
0.5 to 1.5 mg copper (0.14 to 0.42 mg/mL) IV daily as a supplement in TPN; typical adult dose: 0.4 mg copper/day IV.
Intravenous: 0.1-0.2 mg manganese/kg/day (as manganese sulfate) added to TPN. Maximum 0.15-0.8 mg/day. Injection IV: 0.1-0.2 mg manganese/kg/day.
None Documented
None Documented
Terminal half-life is approximately 12-24 hours; clinically relevant for dosing intervals in parenteral nutrition.
Terminal elimination half-life approximately 37 days (range 30–45 days) in whole body; reflects slow turnover in tissues, especially bone and liver. Clinical context: Accumulation occurs with chronic high exposure or impaired biliary excretion (e.g., hepatic disease).
Primarily biliary (>80%) into feces; renal excretion accounts for <5% of total copper elimination under normal conditions.
Primarily fecal (biliary) elimination of unabsorbed manganese; absorbed manganese is excreted mainly in bile (99%) with minimal renal excretion (<1%). Small amounts secreted in pancreatic juice and reabsorbed enterally.
Category C
Category C
Mineral Supplement
Mineral Supplement